Pfizer's profits will fall short of Wall Street estimates next year, as it faces weaker sales of COVID products and squeezed ...

Pfizer shares fell after the company issued weaker-than-expected 2026 guidance, citing lower demand for COVID-19 products and ...

“FDA is doing a thorough investigation, across multiple age groups, of deaths potentially related to coronavirus vaccines,” said Andrew Nixon, spokesperson for the U.S. Department of Health and Human ...

Pfizer has pursued deals of all sizes to build new revenue streams, but the outlook underscores that those investments are ...

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...

About 1 out of 5 people 50 and older who use marijuana reported they'd driven while high at least once during the past year, ...

Pfizer Inc forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...

The company reiterated its 2025 adjusted earnings guidance of $3 to $3.15 a share. It guided for 2025 revenue of $62 billion, compared with its previous forecast of $61 billion to $64 billion.

FDA Commissioner Marty Makary defends agency leadership in NPR interview; New long COVID-19 research links disease to chronic ...

Moderna (MRNA.O), opens new tab did not immediately respond to a Reuters request for comment but has previously said that ...

The U.S. Food and Drug Administration (FDA) is considering adding the strongest safety warning available to COVID-19 vaccines ...

FDA Commissioner Martin Makary discusses vaccine policy, COVID-era decisions and the erosion of trust in government health ...